Skip to main content
SpringerLink
Log in
Book cover

Testosterone pp 329–348Cite as

Comparative pharmacokinetics of testosterone esters

  • Chapter

Abstract

In replacing an endogenous hormone a safe general principle appears to be to mimic, as closely as possible, the normal concentrations of that hormone or its active metabolites. Following this principle testosterone treatment of male hypogonadism should avoid unphysiologically high testosterone serum concentrations to prevent possible side-effects or low concentrations to prevent androgen deficiency.

Keywords

  • Mean Residence Time
  • Testosterone Serum Level
  • Comparative Pharmacokinetic
  • Testosterone Propionate
  • Testosterone Enanthate

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anderson RA, Wu FC (1996) Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metab 81: 896–901

    CrossRef  PubMed  CAS  Google Scholar 

  • Anderson RA, Wallace AM, Kicman AT, Wu FC (1997) Comparison between testosterone en-anthate-induced azoospermia and oligozoospermia in a male contraceptive study. IV. Suppression of endogenous testicular and adrenal androgens. Hum Reprod 128: 1657–1662

    CrossRef  Google Scholar 

  • Behre HM, Nieschlag E (1992): Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 75: 1204–1210

    CrossRef  PubMed  CAS  Google Scholar 

  • Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80: 2394–2403

    CrossRef  PubMed  CAS  Google Scholar 

  • Cantrill AJ, Dewis P, Large DM, Newman M, Anderson DC (1984) Which testosterone replacement therapy? Clin Endocrinol 21: 97–107

    CrossRef  CAS  Google Scholar 

  • Collier PS (1989) Mean residence time: some further considerations. Biopharm Drug Dispos 10: 443–451

    CrossRef  PubMed  CAS  Google Scholar 

  • Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11: 247–264

    CrossRef  PubMed  CAS  Google Scholar 

  • Cunningham GR, Silverman VE, Kohler PO (1978) Clinical evaluation of testosterone en-anthate for induction and maintenance of reversible azoospermia in man. In: Patanelli DJ (ed) Hormonal control of male fertility. Department of Health, Education and Welfare. National Institutes of Health, Bethesda, Md, Publ No (NIH) 78–1097, pp 71–87

    Google Scholar 

  • Cutler DJ (1987) Definition of mean residence times in pharmacokinetics. Biopharm Drug Dispos 8: 87–97

    CrossRef  PubMed  CAS  Google Scholar 

  • Demisch K, Nickelsen T (1983) Distribution of testosterone in plasma proteins during replacement therapy with testosterone enanthate in patients suffering from hypogonadism. Andrologia 15: 536–541

    CrossRef  PubMed  Google Scholar 

  • Fujioka M, Shinohara Y, Baba S, Irie M, Inoue K (1986) Pharmacokinetic properties of testosterone propionate in normal men. J Clin Endocrinol Metab 63: 1361–1364

    CrossRef  PubMed  CAS  Google Scholar 

  • Fukutani K, Isurugi K, Takayasu H, Wakabayashi K, Tamaoki B-I (1974) Effects of depot testosterone therapy on serum levels of luteinizing hormone and follicle-stimulating hormone in patients with Klinefelters syndrome and hypogonadotropic eunuchoidism. J Clin Endocrinol Metab 39: 856–864

    CrossRef  PubMed  CAS  Google Scholar 

  • Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, In., New York Gladtke E, von Hattingberg HM (1977) Pharmakokinetik. 2nd ed Springer, Berlin, Heidelberg, New York

    Google Scholar 

  • Junkmann K (1952) Über protrahiert wirksame Androgene. Arch Path Pharmacol 215:85–92 Junkmann K (1957) Long-acting steroids in reproduction. Recent Prog Horm Res 13: 389–419

    Google Scholar 

  • Maisey NM, Bingham J, Marks V, English J, Chakraborty J (1981) Clinical efficacy of testosterone undecanoate in male hypogonadism. Clin Endocrinol 14: 625–629

    CrossRef  CAS  Google Scholar 

  • Mayer PR, Brazzell RK (1988) Application of statistical moment theory to pharmacokinetics. J Clin Pharmacol 28: 481–483

    PubMed  CAS  Google Scholar 

  • Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ (1997). Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J Pharmacol Exp Ther 281: 93–102.

    PubMed  CAS  Google Scholar 

  • Nankin HR (1987) Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril 47: 1004–1009

    PubMed  CAS  Google Scholar 

  • Nieschlag E, Behre HM (1997) Male contribution to contraception - experimental approaches. In: Nieschlag E, Behre HM (eds) Andrology - Male reproductive health and dysfunction. Berlin, Heidelberg, New York: Springer-Verlag, pp 386–393

    Google Scholar 

  • Nieschlag E, Cüppers HJ, Wiegelmann W, Wickings EJ (1976) Bioavailability and LH-sup- pressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 7: 138–145

    CrossRef  PubMed  CAS  Google Scholar 

  • Partsch CJ, Weinbauer GF, Fang R, Nieschlag E (1995) Injectable testosterone undecanoate has more favourable phamacokinetics and pharmacodynamics than testosterone en-anthate. Eur J Endocrinol 132: 514–519

    CrossRef  PubMed  CAS  Google Scholar 

  • Rajalakshmi M, Ramakrishnan PR (1989): Pharmacokinetics and pharmacodynamics of a new long-acting androgen ester: maintenance of physiological androgen levels for 4 months after a single injection. Contraception 40: 399–412

    CrossRef  PubMed  CAS  Google Scholar 

  • Schulte-Beerbühl M, Nieschlag E (1980) Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril 33: 201–203

    PubMed  Google Scholar 

  • Schürmeyer T, Nieschlag E (1984) Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int J Androl 7: 181–187

    CrossRef  PubMed  Google Scholar 

  • Schürmeyer T, Wickings EJ, Freischem CW, Nieschlag E (1983) Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta endocrinol 102: 456–462

    PubMed  Google Scholar 

  • Skakkebaek NE, Bancroft J, Davidson DW, Warner P (1981) Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol 14: 49–61

    CrossRef  CAS  Google Scholar 

  • Snyder PJ, Lawrence DA (1980) Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 51: 1335–1339

    CrossRef  PubMed  CAS  Google Scholar 

  • Sokol RZ, Swerdloff RS (1986) Practical considerations in the use of androgen therapy. In: Santen JR, Swerdloff RS (eds) Male reproductive dysfunction. Marcel Dekker, New York, pp 211–225

    Google Scholar 

  • Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS (1982) Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37: 425–430

    PubMed  CAS  Google Scholar 

  • van der Vies J (1965) On the mechanism of action of nandrolone phenylpropionate and nandrolone decanoate in rats. Acta endocrinol 49: 271–282

    Google Scholar 

  • van der Vies J (1970) Model studies in vitro with long-acting hormonal preparations. Acta endocrinol 64: 656–669

    PubMed  Google Scholar 

  • van der Vies J (1985) Implications of basic pharmacology in the therapy with esters of nandrolone. In: Eikelboom FA, van der Vies J (eds) Anabolics in the ’80s. Acta endocrinol, suppl 271, 110: 38–44

    Google Scholar 

  • Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Inc, Hamilton, Illinois

    Google Scholar 

  • Wang LZ (1991) The therapeutic effect of domestically produced testosterone undecanoate in Klinefelter syndrome. New Drugs Market 8: 28–32

    CAS  Google Scholar 

  • Weinbauer GF, Marshall GR, Nieschlag E (1986) New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months. Acta endocrinol 113: 128–132

    PubMed  CAS  Google Scholar 

  • Wu FCW, Farley TMM, Peregoudov A, Waites GMH, WHO (1996) Effects of testosterone en- anthate in normal men: experience from a multicenter contraceptive efficacy study. Fertil Steril 65: 626–636

    PubMed  CAS  Google Scholar 

  • Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharma-cokin Biopharm 6: 547–558

    CrossRef  CAS  Google Scholar 

Download references

Authors
  1. Hermann M. Behre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eberhard Nieschlag
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Reproductive Medicine, University of Münster, Domagkstrasse 11, D-48129, Münster, Germany

    Prof. Dr. med. Eberhard Nieschlag & Priv.-Doz. Dr. med. Hermann M. Behre & 

Rights and permissions

Reprints and Permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Behre, H.M., Nieschlag, E. (1998). Comparative pharmacokinetics of testosterone esters. In: Nieschlag, E., Behre, H.M. (eds) Testosterone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72185-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72185-4_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-72187-8

  • Online ISBN: 978-3-642-72185-4

  • eBook Packages: Springer Book Archive

search

Navigation